Dr. Mace Rothenberg - Articles and news items

Pfizer logo

Pfizer’s novel CDK 4/6 inhibitor palbociclib plus letrozole significantly prolonged progression-free survival in patients with advanced breast cancer

Industry news / 7 April 2014 / Pfizer

Final Phase 2 PALOMA-1 data to be presented for potential first-in-class palbociclib…

Pfizer logo

Pfizer and Merck to collaborate on innovative anti-cancer combination studies

Industry news / 5 February 2014 / Pfizer

Agreement to combine Merck’s investigational anti-PD-1 and key Pfizer oncology assets…

Pfizer logo

Pfizer announces positive top-line results from PALOMA-1 evaluating Palbociclib plus letrozole in women with advanced breast cancer

Industry news / 3 February 2014 / Pfizer

Clinical benefit demonstrated for potential first-in-class CDK 4 and 6 inhibitor…

Pfizer logo

Pfizer announces top-line results from two Phase 3 trials of Dacomitinib on patients with refractory advanced non-small cell lung cancer

Industry news / 27 January 2014 / Pfizer

An Ongoing, Third Phase 3 Trial is Evaluating Dacomitinib in First-Line in EGFR-Mutant NSCLC…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...